ADx logo

news and events

Meet us at ADPD Lisbon - Read more

18/01/2019

ADx scientists have developed several new biomarkers based on its own proprietary antibodies. Two of them are new synaptic biomarkers: SNAP25 and Neuronal Pentraxin 2 (NPTX2).

For SNAP25, a high sensitive platform is needed while a NPTX2 measurment can be done with a simple ELISA.

  • COMPARISON BETWEEN TWO ULTRA-SENSITIVE IMMUNOASSAYS (SIMOA VERSUS SINGULEX) FOR DETECTION OF SNAP25 IN CSF      Poster 436 Wednesday 27 March
  • A MONOCLONAL ANTIBODY BASED IMMUNO-ASSAY FOR NEURONAL PENTRAXIN 2 IN CSF       Poster 284 Friday 29 March

ADx has also two new monoclonal antibodies that can measure Neurofilament Light in CSF with ELISA.

A NEUROFILAMENT LIGHT IMMUNO-ASSAY TARGETING THE COIL2 REGION AS A BIOMARKER FOR NEURODEGENERATION     Poster 713 Wednesday 27 March

Further on, we are pursuing the validation of the measurement of Beta Amyloid 42/40 in blood: A promising test for detecting Amyloid plaque burden in the brain. 

  • PRE-ANALYTICAL STABILITY OF PLASMA AMYLOID BETA 1-42 AND 1-40, MEASURED BY A NOVEL SIMOA ASSAY     Poster 220 Wednesday 27 March

 

Lectures with ADx involvement

  • IS CSF BACE1 A GOOD SYNAPTIC BIOMARKER IN ALZHEIMER DISEASE?        13:00-13:15    Sunday 31 March 
  • RELATION BETWEEN CSF AMYLOID-BETA AND TAU LEVELS AND COGNITIVE CHANGE IN A SAMPLE OF COGNITIVELY NORMAL MONOZYGOTIC TWINPAIRS.    12:15-12:30 Sunday 31 March

See you at ADPD in Lisbon end of March.

Back to overview